A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...
Constative on MSN
Weird science studies that ended up being useful
Science isn’t always serious. Sometimes researchers ask questions that seem silly at first, like why toast lands butter-side ...
Explore how oligonucleotides are reshaping therapeutics, diagnostics and CRISPR with rapid, scalable and personalized ...
Ultimately, the collaboration is focused on speeding up progress toward a safer and more resilient food system. As Corbion's ...
Intellia Therapeutics said it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was hospitalized with liver damage.
In a separate 2024 study, researchers also made mice temporarily transparent. The study, published in Science, showed that ...
Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...
ICHORtec GmbH is pleased to announce an expanded research collaboration with the laboratory of Professor Gregory A. Newby in the Department of Genetic Medicine at the Johns Hopkins University School ...
Martin Kampmann’s work, supported by the National Institutes of Science (NIH), maps cellular “decision points” that determine ...
Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback